Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis.
ERJ Open Res. 2021 Mar 8;7(1):00663-2020. doi: 10.1183/23120541.00663-2020. eCollection 2021 Jan.
ERJ Open Res. 2021.
PMID: 33718490
Free PMC article.
FF/UMEC/VI significantly reduced CID risk versus dual therapies (all p<0.001). CONCLUSIONS: Prevention of short-term disease worsening was associated with better long-term clinical outcomes. FF/UMEC/VI reduced CID risk versus dual therapies; this effect may impro …
FF/UMEC/VI significantly reduced CID risk versus dual therapies (all p<0.001). CONCLUSIONS: Prevention of short-term disease worse …
Susceptibility to chronic mucus hypersecretion, a genome wide association study.
Dijkstra AE, Smolonska J, van den Berge M, Wijmenga C, Zanen P, Luinge MA, Platteel M, Lammers JW, Dahlback M, Tosh K, Hiemstra PS, Sterk PJ, Spira A, Vestbo J, Nordestgaard BG, Benn M, Nielsen SF, Dahl M, Verschuren WM, Picavet HS, Smit HA, Owsijewitsch M, Kauczor HU, de Koning HJ, Nizankowska-Mogilnicka E, Mejza F, Nastalek P, van Diemen CC, Cho MH, Silverman EK, Crapo JD, Beaty TH, Lomas DA, Bakke P, Gulsvik A, Bossé Y, Obeidat M, Loth DW, Lahousse L, Rivadeneira F, Uitterlinden AG, Hofman A, Stricker BH, Brusselle GG, van Duijn CM, Brouwer U, Koppelman GH, Vonk JM, Nawijn MC, Groen HJ, Timens W, Boezen HM, Postma DS; LifeLines Cohort study.
Dijkstra AE, et al. Among authors: lomas da.
PLoS One. 2014 Apr 8;9(4):e91621. doi: 10.1371/journal.pone.0091621. eCollection 2014.
PLoS One. 2014.
PMID: 24714607
Free PMC article.
Item in Clipboard
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.
Schmid ST, et al. Among authors: lomas da.
Int J Chron Obstruct Pulmon Dis. 2012;7:687-96. doi: 10.2147/COPD.S34560. Epub 2012 Sep 28.
Int J Chron Obstruct Pulmon Dis. 2012.
PMID: 23055718
Free PMC article.
BACKGROUND: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is to raise the levels of AAT in patients with protease inhibitor phenotype ZZ (Glu342Lys)-inherited AAT deficiency and to protect lung tissues from proteolysis and progression of emph …
BACKGROUND: The major concept behind augmentation therapy with human alpha(1)-antitrypsin (AAT) is to raise the levels of AAT in patients wi …
Item in Clipboard
Cite
Cite